Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody - Wikidata - awgldk - TriplyDB

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

http://www.wikidata.org/entity/Q28239475

about

Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma Deficient mismatch repair: Read all about it (Review)Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF To BRAF or not to BRAF: is that even a question anymore?Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Pre-analytic steps for molecular testing on thyroid fine-needle aspirations: The goal of good results Pathological and molecular advances in pediatric low-grade astrocytoma NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases High frequency of BRAF V600E mutations in ameloblastoma Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas Senescent tumor cells lead the collective invasion in thyroid cancer.Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management A complex secretory program orchestrated by the inflammasome controls paracrine senescence.Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms A protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH domain of Akt1.BRAF V600E mutational status in bile duct adenomas and hamartomas.KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?Differential expression and clinical significance of three inflammation-related microRNAs in gangliogliomas KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.How molecular testing can help (and hurt) in the workup of gliomas.Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.

P2860

Q24314807-F3EB0592-588B-4F28-909D-B3B5BA43EE91 Q26740631-F7A79F86-D5A9-4982-9858-B37C53D1CB33 Q26777288-AE432EAC-577E-4AE3-9D55-315E9EB97EBE Q26796491-12608791-E642-4978-BA16-BFCD60AA477D Q26827212-8136B3F9-DBE6-4BE6-987C-88A6E1375A5C Q26829788-1573FF20-378C-4212-952C-5B9B00413970 Q26853261-DCFFAA53-3F83-4042-9839-A997F0E93909 Q27010085-66A4C875-5220-4F59-B136-1F95797093D0 Q27026123-75FCD395-F391-4CDB-873D-27473DECFF66 Q27852445-0CF07C78-5E93-47DC-83D4-3EC303C56699 Q28250795-CE248939-4575-420A-A3EB-D38391E41AD2 Q28304785-15F7DE08-1C51-454D-9800-7D7329244DD6 Q28305680-C8941524-63CD-49BC-BB08-F58557B91A3F Q33702243-34F6DDBD-7984-4276-BC1C-9698633DC63D Q33852985-D8492B30-4B80-45EC-A5AD-C2ACB1FE17FE Q33861173-E0D731CE-95BF-44C2-8ACC-5D1FE843D225 Q33862255-A092F6B3-57DD-447E-8C08-18EECAF20B92 Q33909962-D167D04A-5ACD-4682-A59A-62BA161EE27A Q34034620-40C9E5F9-C341-4BB7-B351-07FB2DF0836C Q34037190-3C232F51-2A64-41AA-95AF-C5A97B5E8E00 Q34052740-82740D0D-5F18-409E-AE6D-810ABB441970 Q34193749-1FE94FFB-4FF5-4248-9764-20D89DD697F7 Q34206112-CE7FCD61-F88A-4616-83C2-991EA1358D2E Q34207132-C477C204-20CD-4178-94D0-DA9E75552010 Q34520869-3C4EB877-544B-494F-B287-EB166569ABDA Q34782265-B5B49740-B87F-41B7-82EE-5B21A153E821 Q34970350-EC375275-0677-410D-83B0-52D473F1FE4F Q35022501-7666E707-3EA4-42CD-956F-849F0787790E Q35126758-3795E4FF-99DF-4630-9605-D2408318FB4F Q35177372-91FAE50F-D44A-4AFC-9D31-9C99264A565F Q35187723-8895D129-478D-47EE-A2B1-9FE6B7AAB0C1 Q35527097-08627EE7-3431-4DFB-9A07-99B90966EC79 Q35535218-29B19767-3DA3-450B-8A96-405500FF01E3 Q35565384-6BE773D0-57FA-4C1F-8BC0-473E1724C971 Q35578712-71E76384-BB9C-46EA-AABC-56F18175C62F Q35655451-0C3D114F-ADFD-4F9F-A8F8-6798CE8B99E5 Q35751428-830A1060-BF8A-4110-9049-8CE13A4A152E Q35770275-D12FF459-13B4-41F8-9FDF-09CD0710730F Q35869744-B0B3E980-1F2D-44D6-86B9-28A09CE802D5 Q35885523-6CA703F9-0C80-4DE9-909E-590F2EB68C2D

P2860

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

http://www.wikidata.org/entity/Q28239475

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@ast

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@en

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@nl

type

label

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@ast

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@en

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@nl

prefLabel

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@ast

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@en

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@nl

P1433

Q28239475-4F5EF05E-4D1F-4398-82B4-181FC8A23050

P1476

Q28239475-492DA7E6-1CC0-4D1B-BF3F-90BC37FCBC93

P2093

Q28239475-17A81DB0-A964-412E-9089-BDE6C2E280DB

Q28239475-6BFC70B3-01C3-4CE8-9D25-74AB193C1DCB

Q28239475-9996AF1D-BDD6-45C6-90A2-7155FD853AAF

Q28239475-DC1E836B-48AD-4BB1-BDA5-910074744021

Q28239475-E5761761-B2A0-4752-B426-26E6F39303CE

P2860

Q28239475-07D9C1BA-E8E0-40FF-B1AE-7F525E4951A6

Q28239475-09F08E8F-62D5-4EBA-AC27-18A0BF4438B5

Q28239475-0DDB574D-41BA-416F-AEF9-C79B6F76B774

Q28239475-16321BEE-FA1D-46B4-8C7C-60C714A9AD27

Q28239475-3F117B83-9DB1-4ECC-AA3C-21FE47E21051

Q28239475-4470EB10-BAB8-45E4-9C19-553062B152AE

Q28239475-4E550195-50C6-4EDB-BF0B-F258A838D96C

Q28239475-61FAED54-487C-426D-B004-053593131561

Q28239475-6EA8977F-C4B5-40FB-B75D-82C880F6524B

Q28239475-7CA0F6E2-8433-477B-9535-7C54E908FD00

P2888

Q28239475-FA929AD5-8EFD-4DF2-BF67-12A780FF31DF

P304

Q28239475-DA3BC4CD-846E-458D-BC58-67F7C0126C6E

P31

Q28239475-A00C37AD-F837-4FBE-8B11-4B39FDDB7DFC

P3181

Q28239475-C9AA7B8A-B09E-40E5-89B4-24F5D84EA1E3

P356

Q28239475-DF91F18E-012D-4D86-B8C7-F11BBC6AC8ED

P407

Q28239475-4B1E3A1A-D4B1-4606-A985-6BBE5BECA95B

P433

Q28239475-223E5D72-737C-4067-9E7A-54F6E54206FB

P478

Q28239475-3D8AE84B-DD15-42BB-8907-F36E64B91112

P50

Q28239475-161EC5AD-B32C-492E-AD49-A3C5512BD27C

Q28239475-5BE67D29-F570-4AB9-9620-7BE438C144A3

Q28239475-97A7CE6C-32B1-41BB-AF17-13411779FEAE

Q28239475-C2F8A4E8-FF32-4DFA-908C-C6F91D485879

Q28239475-D1882E39-856A-4E4C-A146-90838E23CCBB

P577

Q28239475-FB37B524-AC0B-4199-8F4A-08243227EB6D

P6179

Q28239475-0596B37A-9E5A-4AC7-87C1-4A742F82BA20

P698

Q28239475-2B133E3E-5BAD-4445-B2CD-3E31DE618BF0

P921

Q28239475-23073CF4-16CD-41A9-88E3-0CBACF72A007

Q28239475-F10C0F41-190A-45E5-98E5-694BCEA5E442

P3181

P356

S00401-011-0841-Z

P1433

Acta Neuropathologica

P1476

Assessment of BRAF V600E mutat ...... n-specific monoclonal antibody

@en

P2093

Antje Habel

http://www.w3.org/2001/XMLSchema#string

Genevieve Schindler

http://www.w3.org/2001/XMLSchema#string

Gunhild Mechtersheimer

http://www.w3.org/2001/XMLSchema#string

Hanswalter Zentgraf

http://www.w3.org/2001/XMLSchema#string

Ulrike Ackermann

http://www.w3.org/2001/XMLSchema#string

P2860

Recurrent BRAF mutations in Langerhans cell histiocytosis

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Continuous cultures of fused cells secreting antibody of predefined specificity

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi.

High frequency of BRAF mutations in nevi.

Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping

P2888

s00401-011-0841-z

P304

11-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

448399

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S00401-011-0841-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Preusser

Andreas von Deimling

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020149937

http://www.w3.org/2001/XMLSchema#string

P698

21638088

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry